

UC Irvine

UC Irvine Previously Published Works

Title

Safety and activity of ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

Permalink

<https://escholarship.org/uc/item/9nz3k8g7>

Journal

The Lancet Oncology, 15(10)

ISSN

1470-2045

Authors

Burger, Jan A
Keating, Michael J
Wierda, William G
[et al.](#)

Publication Date

2014-09-01

DOI

10.1016/s1470-2045(14)70335-3

Peer reviewed

Published in final edited form as:

Lancet Oncol. 2014 September ; 15(10): 1090–1099. doi:10.1016/S1470-2045(14)70335-3.

Ibrutinib plus rituximab for patients with high-risk chronic lymphocytic leukaemia: a single-arm, phase 2 study

Jan A. Burger, M.D.¹, Michael J. Keating, M.D.¹ [Professor], William G. Wierda, M.D.¹ [Professor], Elena Hartmann, M.D.², Julia Hoellenriegel, M.S.¹, Nathalie Y. Rosin, Ph.D.¹, Iris de Weerd, M.D.¹, Ghayathri Jeyakumar, M.D.¹, Alessandra Ferrajoli, M.D.¹, Marylou Cardenas-Turanzas, Ph.D.¹, Susan Lerner, M.S.¹, Jeffrey L Jorgensen, M.D.³, Graciela M. Nogueras-González, M.S.³, Gracy Zacharian, M.S.¹, Xuelin Huang, Ph.D.⁴, Hagop Kantarjian, M.D.¹ [Professor], Naveen Garg, M.D.⁵, Andreas Rosenwald, M.D.² [Professor], and Susan O'Brien, M.D.¹ [Professor]

¹Department of Leukemia, MD Anderson Cancer Center, Houston, Texas

²Institute of Pathology, University of Würzburg, Würzburg, Germany

³Department of Hematopathology, MD Anderson Cancer Center, Houston, Texas

⁴Department of Biostatistics, MD Anderson Cancer Center, Houston, Texas

⁵Department of Diagnostic Radiology, MD Anderson Cancer Center, Houston, Texas

Summary

Background—Ibrutinib, an orally administered covalent inhibitor of Bruton tyrosine kinase (BTK), is an effective therapy for patients with relapsed chronic lymphocytic leukemia (CLL). We investigated the activity and safety of the combination of ibrutinib with the monoclonal antibody rituximab (iR) in patients with high-risk CLL.

Methods—In this single-arm, phase 2 study we enrolled 40 patients with high-risk CLL at MD Anderson Cancer Center, Houston, Texas, USA. Patients with symptomatic CLL requiring therapy received 28 day cycles of once-daily ibrutinib 420 mg, together with rituximab (weekly during

© 2014 Elsevier Ltd. All rights reserved.

Correspondence: Jan A. Burger, MD, PhD, Department of Leukemia, Unit 428, The University of Texas MD Anderson Cancer Center, PO Box 301402, Houston, TX 77230-1402, USA, Phone +1-713-563-1487 or (713) 792-1865; FAX +1-713-794-4297, jburger@mdanderson.org.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Primary results were presented in part at the 54th annual meeting of the American Society of Hematology, Atlanta, GA, December 8–11, 2012 and the 55th annual meeting of the American Society of Hematology, New Orleans, LA, December 7–10, 2013

Author Contributions

J.A.B. designed and supervised the trial and correlative studies, analyzed the data and wrote the paper; M.J.K., A.F., S.F., H.K., W.G.W., and S.O.B. contributed to the trial design, clinical patient management, sample collection, and clinical data analysis, and reviewed and approved the paper. E.H. and A.R. analyzed gene expression profiles, J.H., N.Y.R., and I.D.W. analyzed correlative samples, S.L., G.J., M.C., G.N.G., and X.H. performed statistical analyses of the data, and N.G. analyzed serial imaging studies.

Conflict of interest

JAB and SOB received research funding from Pharmacyclics, Inc.; JAB is a consultant for Janssen Pharmaceuticals, Inc.. All other authors declare that they have no conflict of interest.

cycle 1, then once per cycle until cycle 6), followed by continuous single-agent ibrutinib. The primary endpoint was progression-free survival (PFS) in the intention-to-treat population. This study is registered with ClinicalTrials.gov, number NCT01520519 and is no longer accruing patients.

Findings—Between February 28, 2012 and September 11, 2012, we enrolled 40 CLL patients with high-risk disease features. 20 patients had del17p or *TP53* mutations (16 previously treated, 4 untreated), 13 had relapsed CLL with del11q, and 7 patients a PFS < 36 months after frontline chemo-immunotherapy. Toxicity was mainly of mild to moderate severity (grade 1–2). 10 (25%) patients had diarrhea (grade 1 in 9 [22.5%] patients, grade 2 in 1 [2.5%]), bleeding events occurred in 14 (35%) patients (8 [20%] patients with grade 1, 5 [12.5%] patients grade 2, and 1 [2.5%] grade 3), nausea in 15 (37.5) patients (10 [25%] grade 1, 5 [12.5%] grade 2), and fatigue in 7 (17.5%) patients (4 [10%] grade 1, 3 [7.5%] grade 2). Grade 3 infections occurred in 4 patients (10%), no grade 4 or 5 infections occurred. At 18 months, the Kaplan Meier estimate of progression-free survival was 78% (95% CI 60.6–88.5) (del[17p] or *TP53* mutation: 72%, 95% CI: 45.6–87.6)

Interpretation—Ibrutinib in combination with rituximab is a well-tolerated regimen for patients with high-risk CLL. It induces high rates of remissions and has positive impact on QOL in this difficult-to-treat patient population. These encouraging data merit further investigation of the added benefit of rituximab as combination partner for ibrutinib in an ongoing randomized trial, in which single-agent ibrutinib is compared to iR combination therapy (NCT02007044).

Funding—Pharmacyclics, Inc., Cancer Prevention and Research Institute of Texas (CPRIT), Leukemia & Lymphoma Society, NCI Grant P30 CA016672, MD Anderson’s Moon Shot Program in CLL, and MD Anderson Cancer Center Support Grant CA016672.

Introduction

The treatment of patients with chronic lymphocytic leukemia CLL is undergoing fundamental changes¹ due to the emergence of new treatment modalities, such as kinase inhibitors targeting B cell receptor (BCR) signaling^{2, 3} and novel monoclonal antibodies⁴. CLL patients with high-risk cytogenetic abnormalities (deletion 17p*TP53* mutation, or deletion 11q)⁵ can particularly benefit from new kinase inhibitors, given the high response rates to therapy with the BTK inhibitor ibrutinib² and the PI3 kinase delta idelalisib in combination with rituximab³. Chemo-immunotherapy (CIT) regimens, such as fludarabine, cyclophosphamide, rituximab (FCR)⁶ or bendamustine in combination with rituximab (BR)⁷ are effective therapy options for younger patients with lower-risk CLL. However, patients with del(17p) or *TP53* mutations respond poorly to CIT, typically have short remissions^{6, 7}, and consequently a short median life expectancy of only 2 to 3 years after first-line therapy⁸. Patients with relapsed CLL and 11q deletion, who often have extensive lymphadenopathy⁹, are another subset with a poorer prognosis. These patients respond relatively well to chemo-immunotherapy regimens, but have shorter remission durations when compared to those of low-risk patients^{9, 10}. Finally, patients with CLL relapsing early after frontline chemo-immunotherapy (i.e. after less than 24 to 36 months) are another challenging group of high-risk patients^{8, 10} with low response rates and a short survival when re-treated with chemo-immunotherapy^{8, 10}.

Ibrutinib (previously called PCI-32765) is a potent (IC₅₀, 0.5 nM), selective BTK inhibitor which inactivates BTK through irreversible covalent bonding to Cys-481 in the ATP binding domain of the BTK kinase¹¹. For patients with CLL, ibrutinib is administered once-daily orally at a fixed dose of 420 mg continuously until disease progression or toxicity. Early stage clinical trials found single-agent ibrutinib to be particularly active in patients with chronic lymphocytic leukaemia (CLL)^{2, 12} and mantle cell lymphoma (MCL)¹³. The CLL data are based on a phase 1b/2 multicenter study of ibrutinib in 85 patients with relapsed or refractory CLL or SLL². The authors report an ORR of 71%, an additional 15% (in the 840 mg cohort) or 20% (in the 420 mg cohort) of patients had a partial response (PR) with lymphocytosis (PRL). The response was independent of clinical and genomic risk factors present prior to treatment, including advanced-stage disease, number of prior treatments, or presence of 17p deletion. At 26 months, the estimated progression-free survival rate was 75% and the rate of overall survival was 83%. The results from this study led to a Breakthrough Therapy designation for ibrutinib by the U.S. Food and Drug Administration (FDA) in CLL patients with del 17p and the FDA approval of single-agent ibrutinib (Imbruvica™) for previously treated patients with CLL in February 2014. Another recent randomized clinical trial compared ibrutinib with the anti-CD20 antibody ofatumumab in patients with relapsed or refractory CLL or SLL¹⁴. The overall response rate was significantly higher in the ibrutinib group than in the ofatumumab group (42.6% versus 4.1%). An additional 20% of ibrutinib-treated patients had a partial response with lymphocytosis. At a median follow-up of 9.4 months, ibrutinib significantly improved PFS and OS when compared to ofatumumab¹⁴.

In patients with CLL, ibrutinib causes mobilization of CLL cells from tissue sites into the peripheral blood¹⁵, resulting in lymphocytosis during the first weeks of therapy, which is variable among patients and directly related to the presence of the drug. On an intermittent dosing schedule, an increased absolute lymphocyte counts (ALC) rapidly dropped during the off-ibrutinib period, presumably due to increased tissue homing, and then increased again, once ibrutinib was re-started¹². This lymphocytosis is asymptomatic and normalizes after a median time of 6.2 months¹⁶. It is due to the re-distribution of CLL cells from the tissue compartments into the peripheral blood^{12, 15} and therefore must not be confused with lymphocytosis due to disease progression. Preclinical models demonstrated that ibrutinib inhibits CLL cell survival and proliferation¹⁷, as well as leukaemia cell migration towards tissue homing chemokines (CXCL12, CXCL13) and integrin-mediated CLL cell adhesion^{18, 19}; this resulted in transient redistribution lymphocytosis into the PB in an adoptive transfer CLL mouse model¹⁸. Given the redistribution lymphocytosis with single-agent ibrutinib, which can persist in a significant number of patients, the well-recognized efficacy of rituximab in clearing CLL cells from the peripheral blood, and the documented benefit of rituximab in chemotherapy combinations on PFS and OS in untreated patients with CLL⁶, we explored efficacy and safety of the iR combination therapy in high-risk CLL.

Methods

Patients

Forty patients with CLL or small lymphocytic lymphoma (SLL) with high-risk disease were enrolled onto a phase II study of ibrutinib and rituximab at MD Anderson Cancer Center between February and September, 2012. All patients were at least 18 years of age. Inclusion criteria included previously treated high-risk CLL (n=36), and untreated patients with 17p deletion or *TP53* mutation (n=4), given the poor outcome of such patients with CIT. High-risk CLL was defined by the presence of a 17p deletion, *TP53* mutation, or 11q deletion, according to the hierarchical model⁵. Patients with CLL and SLL who had short remission durations of less than 3 years after prior first-line CIT also fulfilled criteria for high-risk disease. Patients with 17p deletion or *TP53* mutation were not required to have received prior therapy, given the poor outcome of such patients with CIT. For previously-treated patients, a 30 day wash out period from prior therapy was required. Patients were required to have an indication for therapy in accordance with the 2008 IWCLL criteria²⁰, adequate renal and hepatic function, defined by an estimated creatinine clearance (CrCl) of > 30 mL/min, an alanine aminotransferase level of no more than 2.5 times the upper limit of the normal range, and absence of active infection. Patients with uncontrolled autoimmune haemolytic anemia (AIHA) or autoimmune thrombocytopenia (ITP), severe hematopoietic insufficiency (absolute neutrophil count < 500/ μ L and/or platelet count < 30,000/ μ L), bleeding diathesis or coagulopathy, recent hemorrhagic events or surgery, or concomitant treatment with warfarin were excluded.

Study design

This phase 2 clinical trial of ibrutinib and rituximab was developed by the investigators in collaboration with Pharmacyclics, Inc. and approved by The University of Texas MD Anderson Cancer Center institutional review board. Informed consent was obtained in accordance with institutional guidelines and the Declaration of Helsinki. Treatment consisted of ibrutinib (420 mg daily by mouth) continuously daily (one cycle = 28 days), in combination with weekly rituximab (375 mg/m² intravenously) for weeks 1–4 (cycle 1) to front-load during time of highest intravascular CLL cell burden, then rituximab was given once every 4 weeks until cycle 6, followed by single-agent ibrutinib. Patients remained on treatment until disease progression or toxicities or complications precluded further therapy. Ibrutinib was held for any grade 3–4 toxicity until the adverse event returns to baseline or resolves complete. Rituximab was held for any Grade 4 toxicity or for any rituximab-related, clinically significant, unmanageable Grade 3 adverse events until the adverse event returns to baseline or resolves complete. Dose modifications were not permitted. Clinical and laboratory assessment were performed every week during cycle 1, then once every 4 weeks until cycle 6, and then every 3 months thereafter while patients remained on study.

Pretreatment evaluation

Pre-treatment evaluation included history, physical examination, complete blood count with differential, and chemistry profile consisting of serum creatinine, electrolytes, albumin, calcium, uric acid, lactate dehydrogenase, and alanine transaminase. Serum immunoglobulin (Ig) levels, β 2-microglobulin levels, and peripheral T-cell lymphocyte subset analysis by

flow cytometry were also measured. Bone marrow aspiration was performed before therapy, including infiltration assessment, immunophenotype by flow cytometry, Ig heavy chain gene mutation analysis by polymerase chain reaction. Standard metaphase karyotype analysis and genomic abnormalities were detected by fluorescent in situ hybridization (FISH) using standard CLL probes (Abbott Molecular).

Response and safety assessments, quality of life

Response assessment for PFS and overall response rate (ORR) included clinical assessment, along with radiologic examinations with computerized tomography (CT) scans of the chest, abdomen, and pelvis at baseline, after 3 or 6 months (time-point at the discretion of the treating physician), and after 12 months. Bone marrow aspirations and biopsies were performed and evaluated by morphology and flow cytometry at baseline and after 3, 6, and 12 months, and once every 12 months thereafter. Minimal residual disease (MRD) assessment was performed using 4-color flow cytometry. Quantitative MRD results were categorized as positive ($\geq 0.01\%$) or negative (lower than 0.01%)²¹. Responses were evaluated according to the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria²⁰, with the exception that lymphocytosis was not the sole criterion for disease progression. Patients with persistent lymphocytosis, who otherwise were considered to have a partial response by all other measures, were considered to have a partial response with lymphocytosis. To assess for disease progression on therapy, best response, i.e. the true nadir was considered as baseline. For example, if a patient had normalization or major reduction of ALC on iR therapy, but later developed progressive lymphocytosis, this patient would be considered to have PD, especially in the context of other signs (clinical and laboratory) of disease progression, such as progressive cytopenias, increasing levels of LDH, and/or organomegaly and/or progressive lymphadenopathy. Safety monitoring was performed weekly for the first month, then monthly until month 6, and every 3 months thereafter. Adverse events were graded with the use of the National Cancer Institute Common Terminology Criteria for Adverse Events, version 4.0. Hematologic toxic effects were graded according to the IWCLL system. The EORTC QLQ-C30 questionnaire was used to assess health-related quality of life (QOL) as detailed in the online supplement.

BTK probe assay, chemotaxis, plasma cytokine/chemokine assays, gene expression analysis

BTK target occupancy during iR treatment was tested using a fluorescently tagged derivative of ibrutinib (PCI-33380). Chemotaxis of CLL cells was assayed across polycarbonate Transwell inserts. Plasma levels of CCL3 and CCL4 before and during treatment were assessed by ELISA using Quantikine Kits (R&D Systems). For all other cytokines we used multiplex bead assays according to the manufacturer's instructions (EMD Millipore, Billerica, MA, USA). For gene expression analyses, RNA was isolated from CD19-purified CLL cells from 10 randomly selected patients' peripheral blood mononuclear cells (PBMC), collected at baseline and after 7 and 28 days on iR treatment. Gene expression was tested with HG U133 plus 2.0 oligonucleotide arrays from Affymetrix (Affymetrix, Santa Clara, CA) in 8 patients samples (2 patients had insufficient amounts of RNA), following the Affymetrix standard protocols. Further details are provided in the online supplement.

Statistical Analysis

The primary endpoint was to assess the activity of the combination of ibrutinib and rituximab in high-risk CLL, with progression-free survival (PFS) as the primary endpoint. PFS was defined as the time between initiation of study treatment and the date of first documented disease progression or death from any cause. The secondary endpoints were overall survival (OS), overall response rate (ORR), response rates and survival in biological subgroups, rates of treatment-related and –unrelated adverse effects, quality of life (QOL), and changes in correlative biomarkers during treatment. We determined that with a sample size of 40 patients, if the new treatment improves the progression-free survival (PFS) in high-risk CLL by 2 months when compared to available data in a comparable group of patients treated with standard chemo-immunotherapy¹⁰, the power is > 80%. Progression free survival was defined as the time interval from treatment to progressive disease or death, whichever happened earlier. Patients in complete remission (CR), partial remission (PR) or stable disease (SD) are all counted as progression-free. Due to the characteristic activity of ibrutinib, which typically induces a transient lymphocytosis during the first months of therapy, which is due to a re-distribution of CLL cells from the tissue compartments (bone marrow, secondary lymphatic tissues) into the peripheral blood, increases in lymphocyte counts can be expected (although in this combination with rituximab are less likely) and was not considered as a sign of progressive disease. For interim analyses, the PFS was continuously monitored, and accrual would have been terminated early if the probability of improving PFS by 2 months is less than 0.01. The Department of Biostatistics provided and maintained a website (“Clinical Trial Conduct”) for enrolling patients on this study and evaluating the efficacy monitoring rules described above. This analysis shows the final data from our study, extracted on November 18, 2013. Descriptive statistics were used to summarize the patient cohorts at defined time-points. Fisher’s exact test and Wilcoxon rank test were used in the univariate analyses to compare groups. Wilcoxon signed ranks test for paired data was used to determine if there were differences in the distribution between time points in the QOL outcomes. The safety analysis was performed based on the intent-to-treat and efficacy analysis was analyzed only using the evaluable cohort (39 patients). Toxicity was reported by type, frequency and severity. Worst toxicity grades per patient were tabulated for selected adverse events and laboratory measurements. Survival times were estimated using the Kaplan-Meier method. Patients were censored for progression-free survival at the last clinical assessment before receipt of new anti-leukemia therapy, or after loss to follow-up, whichever occurred first. Patients were censored for overall survival at the last known alive date. Statistical analyses were conducted using STATA/SE version 12.1 statistical software (Stata, LP, College Station, TX) and GraphPad Prism version 6.00 for Windows (GraphPad Software, La Jolla California, 2013). This study is registered with ClinicalTrials.gov, number NCT01520519.

Role of the funding sources

The study was supported by Pharmacylics, Inc. The clinical investigators were responsible for the design of the study protocol and analysis plan, together with Pharmacylics. The investigators and their respective research teams collected all of the data, and compiled and analyzed the data. The investigators had full access to the data and analyses for compilation of this manuscript. JAB wrote the first draft of the manuscript, which was carefully

reviewed by Pharmacyclics, Inc. and all co-authors, who approved the final submitted version. The corresponding author had full access to all of the data and had final responsibility to submit for publication.

Results

Patients and treatment

Patients were accrued between February 28, 2012 and September 11, 2012 at MD Anderson Cancer Center. Baseline characteristics of the forty patients are summarized in Table 1; they include a median age of 63 (range 35–82) and a median of 2 prior therapies. 20 patients had del17p or *TP53* mutation (4 without prior therapy), and 13 patients had del11q. Thirty-two patients had unmutated *IGHV* genes, only one patient had mutated *IGHV* genes, the remaining seven patients had inconclusive *IGHV* results. At a median follow up of 16.8 months (range 2.3–20.5 months), 31 patients continue on therapy (14 of 20 with del17p or *TP53* mutation) and 9 (22.5%) discontinued treatment. Among the 9 patients that discontinued, 2 patients died while on study, and 6 died after study discontinuation. One patient that died on study had an unrelated infectious complication (pneumonia and CNS abscesses) during the 2nd cycle of treatment, the other patient died in remission from unknown cause (during sleep). The 6 other patients that died after study discontinuation died from infectious complications or disease progression (for details please see supplemental Table S3). Two patients (5%) discontinued therapy because of toxicity (one grade 3 mucositis, one grade 3 recurrent ear and pulmonary infections). One patient stopped because of resistant pneumonia, and another with progressive COPD. Three patients (7.5%) had disease progression after 176, 395, and 429 days, one of them with Richter's transformation. The post-remission treatments are detailed in the supplemental Table S3.

Treatment responses

Thirty-nine patients were evaluable for response assessment per 2008 IWCLL guidelines: 34 (87%) achieved partial remission (PR), and three (8%) complete remission (CR) as best response, accounting for an ORR of 95%. Notably, two of three patients that achieved a CR were patients with del17p or *TP53* mutation who were previously untreated. One patient in CR was negative for MRD by flow cytometry. The ORR in the 20 patients with del17p or *TP53* mutation was 90% (16 PR, 2 CR). The median time to achieve a response was 5.72 months (IQR 5.32–6.87), and the median duration of response was 15.44 months (IQR 10.55–18.27). The two patients that did not respond were patients that discontinued therapy early, after 5 or 2 cycles of treatment, due to toxicity (mucositis, patient 3 in Table S3) and infectious complications (patient 5 in Table S3). Blood lymphocytosis peaked at a median of one week of iR therapy, and then continuously declined (Figure 1A). CT scans at 6 months and 12 months (Figure 1B) revealed more than 50% reduction in lymphadenopathy in 29 of 34 evaluable patients (85%). At 18 months, an estimated 78% of patients were free of progression (95% confidence interval [CI]: 60.58–88.45); in patients with del(17p) or *TP53* mutation, the PFS was 72% (95% CI: 45.56–87.55). The estimated OS of all patients at 18 months was 84% (95% CI: 67.22–92.39); for patients with del(17p) or *TP53* mutation, the estimated OS was 78% (95% CI: 51.99–91.36, Figure 2). In 38 evaluable patients, the lymphocyte count normalized (absolute lymphocyte count, $<4 \times 10^9$ cells/L) or was reduced

by 50% from baseline after 7 months (Figure 1A). This coincided with a notable reduction in lymphnode size (Figure 1B) and spleen size (supplemental Figure S1). Sustained improvement in cytopenias, defined as improvement by more than 50% from baseline or a hemoglobin level higher than 11 g/dL, or a platelet count higher than 100,000/ μ L lasting for 2 cycles without transfusion or administration of growth factors, was observed in 15 of 24 patients with baseline thrombocytopenia, and 15 of 17 with anemia (supplemental Figure S2). Serial bone marrow evaluations revealed a significant decrease in bone marrow infiltration by the CLL cells (Figure 1C). Due to the early and more complete resolution of lymphocytosis when compared to single-agent ibrutinib², cases of partial remissions with lymphocytosis were infrequent at earlier time points (3 cases [8%] after 6 cycles), and absent after 12 months of treatment.

Quality of life (QOL)

Comparing differences in HRQOL between baseline and during therapy, we noted that iR-treated patients showed significant improvement in overall health and quality of life after 6 and 12 months (table 2, and supplemental table 1), which coincided with a significant weight gain at 3 and 6 months (supplemental Figure S3).

Safety

Treatment was well tolerated, with respiratory infections (8 cases of pneumonia [grade 2, 3] and 9 cases of upper respiratory infections [grade 2]) being the most common adverse events (AE). There were also grade 2–3 possibly related AE of mucositis (n=3), and peripheral neuropathy (n=5), and one case of a grade 2 subdural hematoma in a 70 year old male, who fell and subsequently developed headaches. This patient did not require any intervention; ibrutinib was initially held, and later restarted. Milder toxicities included grade 1–2 diarrhea (n=17), bruising and rash (n=15), nausea or acid reflux (n=10, grade 1, 2), fatigue (n=7), and bone pain, myalgia/arthralgia (n=13). Hematologic toxicities included grade 2–3 neutropenia (n=4) and anemia (n=2). The related and unrelated toxicities are summarized in the supplemental Figure S4 and in the supplemental Tables S3, S4.

Gene expression response of CLL cells during iR therapy

We observed a relatively homogenous gene expression response of CLL cells during iR therapy. Supplemental Figure S7A displays heat maps that illustrate the most down-regulated genes in CLL cells after 7 and 28 days of iR therapy relative to baseline gene expression. The genes with known and potentially relevant function are annotated on Figure S7A, and include the chemokine CCL3, early growth response protein genes 1,2, and 3 (EGR 1,2,3), and CD72. We provide more details in the supplemental Tables S4–7 where we display the most up- and down-regulated genes after 7 and 28 days of therapy. Interestingly, we found that the pattern of down-regulated genes mirrors the genes up-regulated in CLL cells in nurselike cell cocultures²² previously characterized as BCR-regulated genes, as illustrated in Figure S7B.

Other laboratory markers

The mean beta-2-microglobulin (β 2M) level before therapy was 5.2 mg/L (n=40), which significantly decreased during iR therapy to 3.2 mg/L after 3 months (n=37), to 2.3 mg/L after 6 months (n=35), to 2.7 mg/L after 12 months (n=35), and to 2.6 mg/L after 18 months (n=5, supplemental Figure S8A). The fact that β 2M level plateau rather than normalize over time is of interest and may be due to residual disease. IgG and IgA immunoglobulin levels did not significantly change during iR therapy over 18 months of follow up. We noted a decline in IgM levels, which was not statistically significant (supplemental Figure S8B). Mean pre-treatment IgM levels of 110 mg/dL (n=39) dropped to 72 mg/dL after 3 months (n=37), to 66 mg/dL after 6 and 12 months (n=36 and 35, respectively), and to 29 mg/dL after 18 months (n=4). T cells and T cell subset numbers also changed during iR therapy (supplemental Figure S8E–G). Elevated numbers of CD3⁺ cells prior to treatment (mean: 2820/ μ L, n=30) remained at 3029/ μ L after 3 months (n=36), but then declined to 1919 after 6 months (n=33), and to 1606 after 12 months (n=32). This was due to changes in both, CD4⁺ and CD8⁺ T cells. Mean CD3⁺ CD4⁺ cell counts significantly decreased during iR therapy from 1369/ μ L prior to treatment (n=35) to 1240/ μ L after 3 months (n=37), to 841/ μ L after 6 months (n=33), and to 681/ μ L after 12 months (n=32, p=0.014). Mean CD3⁺ CD8⁺ cell counts slightly increased from 1527/ μ L prior to therapy (n=35) to 1649/ μ L after 3 months (n=37), but then declined to 1090/ μ L after 6 months (n=33), and 885/ μ L after 12 months (n=32). T cell counts in individual patients before and during iR therapy are depicted in the Supplement (supplemental Figures S5, S6).

BTK occupancy and chemotaxis

We found that iR treatment resulted in a full occupancy of BTK at both time points (supplemental Figures S9A). To explore iR therapy effects on CLL cell migration in vivo, serial blood CLL samples were tested in chemotaxis assays. We found that iR therapy significantly reduced CLL cell chemotaxis toward CXCL12 and CXCL13 (supplemental Figures S9B). For example, the mean (\pm SEM) relative numbers of CLL cells from 6 patients migrating toward CXCL13 decreased from 1906 (\pm 556) before therapy to 666 (\pm 133) after 14 days and 1109 (\pm 401) after 28 days of therapy.

Plasma cytokine and chemokine levels

Serial plasma samples were assayed for changes in cytokine and chemokine levels at earlier and later time points. We found significant reductions in plasma levels of a number of cytokines that are either CLL cell-derived (CCL3, CCL4) or originate from cells in the microenvironment (CXCL13). For example, after 14 and 28 days of iR treatment, elevated median plasma levels of CCL3 and CCL4 significantly decreased from 139.6 (\pm 40.4) pg/mL to 6.9 (\pm 0.9) pg/mL, and from 578.6 (\pm 103.9) pg/mL to 68.7 (\pm 7.2) pg/mL, respectively (figure 7C). Plasma levels of CCL19 TNF α (Figure 5C), and CCL21 (data not shown) were also significantly reduced after 1 month. These chemokines, in concert with CXCL12 and CXCL13, are involved in B cell homing into lymph nodes. CXCL13 plasma levels decreased significantly from 94.6 (\pm 16.3) pg/mL to 32.26 (\pm 6.9) pg/mL after 1 month and to 28.7 (\pm 6.8) pg/mL after 3 months of iR therapy. Notably, levels of CXCL12, a chemokine secreted by mesenchymal stromal cells remained stable during treatment (Figure S9).

Discussion

The combination of ibrutinib and rituximab induces a high rate of responses in our patients with high-risk CLL, with an ORR of 95% at a median follow-up of 17 months. In this study, responses are durable with 78% of patients free of disease progression, and 84% remained alive at 18 months. One of the most distinguishing findings in this study is the short duration of ibrutinib-associated redistribution lymphocytosis (Figure 1A). Consequently, there are fewer cases of patients with persistent lymphocytosis, even at early time points, and, compared to the reported single-agent experience, objective remissions are achieved in a higher proportion of patients. Specifically, the ORR with iR was more than 20% higher than with single agent ibrutinib (95% ORR with iR vs. 71%² or 42.6%¹⁴ with single-agent ibrutinib in two different trials). Cross trial comparisons have limitations, but this earlier and more complete clearance of CLL cells from the peripheral blood presumably is due to the addition of rituximab. While 20% of patients treated with 420 mg ibrutinib daily as single agent had persistent lymphocytosis at 12 months^{2, 16}, persistent lymphocytosis was rare after 6 months of iR (8%), and absent after 12 months of combination therapy (Figure 1A). Similar findings of a blunted and shortened duration of lymphocytosis recently were reported for the combination of the PI3K δ inhibitor idelalisib with rituximab in patients with relapsed CLL³.

The relevance of clearance of CLL cells from the PB during ibrutinib therapy remains largely unknown. Woyach and colleagues recently provided data demonstrating that persistent lymphocytosis during ibrutinib therapy was not associated with an adverse outcome¹⁶, suggesting that elimination of CLL cells from the PB, traditionally a key response criterion, may not be a necessary goal of ibrutinib-based therapy. In this study we evaluated the activity of ibrutinib in combination with rituximab. It is known that rituximab, which has very limited clinical activity in CLL as a single agent, substantially increases PFS and OS when added to fludarabine and cyclophosphamide in previously untreated patients with CLL^{6, 23}. Its role as combination partner with ibrutinib, beyond effective clearance of PB from CLL cells cannot be further defined in this study and is currently addressed in an ongoing randomized trial of ibrutinib versus iR (NCT02007044).

Besides BTK, ibrutinib can also interfere with the activity of other kinases that contain a modifiable cysteine residue homologous to Cys-481 in BTK, such as interleukin-2 inducible tyrosine kinase (ITK)²⁴. ITK is expressed in NK and T cells, and Kohrt et al. recently reported that ibrutinib antagonizes rituximab's anti-lymphoma activity in a mouse model, based on ibrutinib's inhibition of FcR-stimulated NK cell function, specifically antibody-dependent cell-mediated cytotoxicity (ADCC)²⁵. However, the relative contribution and importance of NK cells, monocytes, or other effector cells for CD20 antibody-mediated killing of B cells remains controversial. Other mechanisms of rituximab-induced toxicity towards malignant B cells, which are independent of NK cell function (via induction of direct cell death and complement-dependent cytotoxicity) have been documented. The rapid clearance of CLL cells from the PB in this trial suggest that any antagonistic activity of ibrutinib does not play a significant role in blood stream clearance of CLL cells. Beyond that, to define if the addition of rituximab impacts PFS or OS, we will need to wait for mature data from the randomized trial of ibrutinib versus iR. If PFS or OS are prolonged

with the addition of rituximab, this would suggest a lack of ibrutinib-rituximab antagonism in CLL in the human disease setting.

The PFS of 78% (95% CI: 60.58–88.45; 72% PFS [95% CI: 45.56–87.55] in patients with del[17p] or *TP53* mutation) and OS of 84% (95% CI: 67.22–92.39; 78% OS [95% CI: 51.99–91.36] in patients with del[17p] or *TP53* mutation) at 18 months (Figure 2) compare very favorably to other therapy options for similarly high-risk patients with CLL, especially in the relapsed disease setting. In a retrospective single-center analysis of 174 patients, median PFS and OS in CLL patients with del(17p) was higher with ibrutinib therapy when compared to any other therapy²⁶, and the high response rate observed in this study supports the conclusion that, among the approved therapies, ibrutinib alone or in combination with rituximab represents a highly effective treatment for high-risk CLL. Besides PFS and OS, improvement in QOL has become one of the major end points in clinical trials with novel anticancer agents, especially in incurable diseases. CLL has a profound impact on QOL, which is particularly low in patients with advanced stage disease, older age, fatigue, co-morbidity, and active treatment²⁷. Eichhorst reported moderate improvement in QOL after FC therapy²⁸. Our finding of a significant improvement of QOL during iR therapy supports the notion that effective CLL therapy improves QOL.

The gene expression profile data (Figure S7) demonstrate on-target down-regulation of BCR- and NF κ B-regulated genes which are considered central for CLL cell survival and interactions within the lymphoid tissue microenvironment²⁹. For example, the chemokine CCL3, which is up-regulated in CLL cells after nurselike cell co-culture and after BCR triggering²², can attract accessory cells, such as T cells and monocytes into the lymphoid tissues, fostering the influx of cells that support the survival and growth of the CLL clone. CLL cells isolated from CLL lymph nodes contain high levels of CCL3²⁹, and high CCL3 plasma levels predict for inferior outcome in CLL³⁰. Importantly, down-modulation of CCL3 during iR therapy was seen at the gene expression level and in patients' plasma samples, serving as a cross validation of the data, and corroborating the value of CCL3 as a plasma biomarker for responses to kinase inhibitors that target BCR signalling such as ibrutinib¹⁸ and idelalisib³¹.

The biologically most interesting correlative findings in this study are the normalization of high PB T cell counts, and the normalization of a number of cytokines/chemokines, as well as β 2 microglobulin (β 2M) levels. T cell numbers of both, the CD4 and CD8 sub-sets are increased in untreated patients with CLL, and the normalization of these cell populations during iR therapy (Figure S8) can be interpreted as a sign of co-evolution and interdependence between T cells and CLL cells. Significant reductions in plasma levels of TNF α , the lymph node homing chemokines CCL19 and CXCL13, as well as β 2M (Figure S9) provide further insight into the targets and consequences of iR therapy. Together with the inhibition of chemotaxis of CLL cells isolated from patients on iR therapy (Figure S9B), which was expected from the pre-clinical work^{18, 19} and which is due to direct effects of BTK inhibition on chemokine receptor signalling^{18, 19}, the reduction of CCL19 and CXCL13 plasma levels (Figure S9C) points towards additional mechanism for redistribution of tissue CLL cells into the PB during ibrutinib therapy. CCL19 and CXCL13 are important chemokines that coordinate normal and malignant B cell homing into secondary lymphoid

tissues³², and their down-modulation during iR therapy is interpreted as additional, indirect mechanism for CLL cell mobilization by ibrutinib. Significant reduction of elevated TNF α and β 2M levels support the important role of these proteins in disease progression and prognosis, but there are no data to suggest a mechanism of regulation of these proteins by iR therapy.

In summary, our data demonstrate that the combination of ibrutinib and rituximab is an effective therapy for CLL patients with high-risk disease, where it induces high ORR and durable remissions in the majority of patients. Treatment is well tolerated and is associated with significant improvements in QOL. The correlative studies demonstrate that this therapy normalizes multiple cellular and plasma markers of disease activity. A randomized study of ibrutinib versus ibrutinib plus rituximab is ongoing and will determine whether the addition of rituximab, besides abridging the initial lymphocytosis, improves PFS and/or OS.

Research in context

Systematic review

We searched PubMed for articles published in English after January 1, 2005 to identify agents used to treat patients with high-risk chronic lymphocytic leukaemia (alemtuzumab, chlorambucil, rituximab, ofatumumab, obinutuzumab, fludarabine, cyclophosphamide, and lenalidomide). We identified primary publications for these agents^{6, 8, 23, 33} which show that low response rates and short remissions are a major problem. Only single-agent ibrutinib trials have been published to date^{12, 14, 34, 35}. To our knowledge, no other data are available for ibrutinib combination therapy.

Interpretation

We have shown that ibrutinib in combination with rituximab is active and safe for the treatment of patients with high-risk chronic lymphocytic leukemia. Larger randomized trials are warranted to confirm these findings.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

The authors thank the patients who participated in this trial and their families, and the study investigators and coordinators at MD Anderson, especially Benjamin Hayes for sample and data collection and Jeannice Theriot for expert editorial assistance.

References

1. Hallek M. Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies. *Blood*. 2013; 122(23):3723–3734. [PubMed: 24065239]
2. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. *The New England journal of medicine*. 2013; 369(1):32–42. [PubMed: 23782158]

3. Furman RR, Sharman JP, Coutre SE, Cheson BD, Pagel JM, Hillmen P, et al. Idelalisib and Rituximab in Relapsed Chronic Lymphocytic Leukemia. *The New England journal of medicine*. 2014
4. Goede V, Fischer K, Busch R, Engelke A, Eichhorst B, Wendtner CM, et al. Obinutuzumab plus Chlorambucil in Patients with CLL and Coexisting Conditions. *The New England journal of medicine*. 2014
5. Dohner H, Stilgenbauer S, Benner A, Leupolt E, Krober A, Bullinger L, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. *The New England journal of medicine*. 2000; 343(26):1910–1916. [PubMed: 11136261]
6. Hallek M, Fischer K, Fingerle-Rowson G, Fink AM, Busch R, Mayer J, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. *Lancet*. 2010; 376(9747):1164–1174. [PubMed: 20888994]
7. Fischer K, Cramer P, Busch R, Bottcher S, Bahlo J, Schubert J, et al. Bendamustine in combination with rituximab for previously untreated patients with chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group. *J Clin Oncol*. 2012; 30(26):3209–3216. [PubMed: 22869884]
8. Stilgenbauer S, Zenz T. Understanding and managing ultra high-risk chronic lymphocytic leukemia. *Hematology / the Education Program of the American Society of Hematology American Society of Hematology*. 2010; 2010:481–488.
9. Dohner H, Stilgenbauer S, James MR, Benner A, Weilguni T, Bentz M, et al. 11q deletions identify a new subset of B-cell chronic lymphocytic leukemia characterized by extensive nodal involvement and inferior prognosis. *Blood*. 1997; 89(7):2516–2522. [PubMed: 9116297]
10. Badoux XC, Keating MJ, Wang X, O'Brien SM, Ferrajoli A, Faderl S, et al. Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL. *Blood*. 2011; 117(11):3016–3024. [PubMed: 21245487]
11. Burger JA, Buggy JJ. Emerging drug profiles: Bruton tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765). *Leuk Lymphoma*. 2013
12. Advani RH, Buggy JJ, Sharman JP, Smith SM, Boyd TE, Grant B, et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies. *J Clin Oncol*. 2013; 31(1):88–94. [PubMed: 23045577]
13. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma. *The New England journal of medicine*. 2013
14. Byrd JC, Brown JR, O'Brien S, Barrientos JC, Kay NE, Reddy NM, et al. Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia. *The New England journal of medicine*. 2014
15. Burger JA, Montserrat E. Coming full circle: 70 years of chronic lymphocytic leukemia cell redistribution, from glucocorticoids to inhibitors of B-cell receptor signaling. *Blood*. 2013; 121(9):1501–1509. [PubMed: 23264597]
16. Woyach JA, Smucker K, Smith LL, Lozanski A, Zhong Y, Ruppert AS, et al. Prolonged lymphocytosis during ibrutinib therapy is associated with distinct molecular characteristics and does not indicate a suboptimal response to therapy. *Blood*. 2014; 123(12):1810–1817. [PubMed: 24415539]
17. Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, et al. Bruton's tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. *Blood*. 2011
18. Ponader S, Chen SS, Buggy JJ, Balakrishnan K, Gandhi V, Wierda WG, et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo. *Blood*. 2012; 119(5):1182–1189. [PubMed: 22180443]
19. de Rooij MF, Kuil A, Geest CR, Eldering E, Chang BY, Buggy JJ, et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia. *Blood*. 2012; 119(11):2590–2594. [PubMed: 22279054]
20. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Dohner H, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International

- Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. *Blood*. 2008; 111(12):5446–5456. [PubMed: 18216293]
21. Rawstron AC, Villamor N, Ritgen M, Bottcher S, Ghia P, Zehnder JL, et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. *Leukemia*. 2007; 21(5):956–964. [PubMed: 17361231]
 22. Burger JA, Quiroga MP, Hartmann E, Burkle A, Wierda WG, Keating MJ, et al. High-level expression of the T-cell chemokines CCL3 and CCL4 by chronic lymphocytic leukemia B cells in nurselike cell cocultures and after BCR stimulation. *Blood*. 2009; 113(13):3050–3058. [PubMed: 19074730]
 23. Keating MJ, O'Brien S, Albitar M, Lerner S, Plunkett W, Giles F, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. *J Clin Oncol*. 2005; 23(18):4079–4088. [PubMed: 15767648]
 24. Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. *Blood*. 2013; 122(15):2539–2549. [PubMed: 23886836]
 25. Kohrt HE, Sagiv-Barfi I, Rafiq S, Herman SE, Butchar JP, Cheney C, et al. Ibrutinib antagonizes rituximab-dependent NK cell-mediated cytotoxicity. *Blood*. 2014; 123(12):1957–1960. [PubMed: 24652965]
 26. Stephens DM, Ruppert AS, Jones J, Woyach J, Maddocks K, Jaglowski S, et al. Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed Del(17p13.1) karyotype at a single center. *Leukemia*. 2014
 27. Shanafelt TD, Bowen D, Venkat C, Slager SL, Zent CS, Kay NE, et al. Quality of life in chronic lymphocytic leukemia: an international survey of 1482 patients. *British journal of haematology*. 2007; 139(2):255–264. [PubMed: 17897301]
 28. Eichhorst BF, Busch R, Obwandner T, Kuhn-Hallek I, Herschbach P, Hallek M. Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study Group. *J Clin Oncol*. 2007; 25(13):1722–1731. [PubMed: 17389338]
 29. Herishanu Y, Perez-Galan P, Liu D, Biancotto A, Pittaluga S, Vire B, et al. The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia. *Blood*. 2011; 117(2):563–574. [PubMed: 20940416]
 30. Sivina M, Hartmann E, Kipps TJ, Rassenti L, Krupnik D, Lerner S, et al. CCL3 (MIP-1{alpha}) plasma levels and the risk for disease progression in chronic lymphocytic leukemia (CLL). *Blood*. 2010
 31. Hoellenriegel J, Meadows SA, Sivina M, Wierda WG, Kantarjian H, Keating MJ, et al. The phosphoinositide 3'-kinase delta inhibitor, CAL-101, inhibits B-cell receptor signaling and chemokine networks in chronic lymphocytic leukemia. *Blood*. 2011; 118(13):3603–3612. [PubMed: 21803855]
 32. Burger JA. Chemokines and chemokine receptors in chronic lymphocytic leukemia (CLL): from understanding the basics towards therapeutic targeting. *Seminars in cancer biology*. 2010; 20(6): 424–430. [PubMed: 20883788]
 33. Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J, et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. *Blood*. 2002; 99(10):3554–3561. [PubMed: 11986207]
 34. Byrd JC, Furman RR, Coutre SE, Flinn IW, Burger JA, Blum KA, et al. The Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib (PCI-32765) Promotes High Response Rate, Durable Remissions, and Is Tolerable in Treatment Naïve (TN) and Relapsed or Refractory (RR) Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) Patients Including Patients with High-Risk (HR) Disease. New and Updated Results of 116 Patients in a Phase Ib/II Study *Blood*. 2012; 120(21) Abstract 189.
 35. O'Brien S, Furman RR, Coutre SE, Sharman JP, Burger JA, Blum KA, et al. Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial. *Lancet Oncol*. 2014; 15(1):48–58. [PubMed: 24332241]




Figure 1. Changes in lymphocyte counts (A) lymph node sizes (B) and bone marrow (C) during iR therapy

(A) Trended absolute lymphocyte counts (ALC) in CLL patients during therapy with ibrutinib and rituximab. The horizontal axis shows the time of treatment. Please note the early, transient lymphocytosis, which peaked during the first week of therapy, and then continuously declined and resolved. (B) Best responses in 34 evaluable patients evaluated by computed tomography scan for change from baseline in the sum of the largest diameter of each target lesion; negative values indicate tumor shrinkage. Among the 34 patients with measurable lesions both at baseline and after baseline, all 34 patients (100%) had

improvements in lymphadenopathy, as assessed by changes in the sums of the products of the perpendicular dimensions (SPD) of index lesions. The dashed line shows the percentage change that represents the criterion for lymphadenopathy response.(C) The bar diagrams depict the mean (\pm SEM) relative numbers of bone marrow lymphocytes before therapy and after 3, 6, and 12 months of iR therapy. There was a continuous significant decline in marrow lymphocytes, indicating improvements in marrow infiltration by the CLL cells.




Figure 2. Kaplan–Meier curves for overall survival (OS) and progression-free survival (PFS)
 The top panels show the probability of overall survival (left hand panel) and progression-free survival (right hand panel) for all 40 patients. The bottom graphs depict OS and PFS with respect to the del(17p) status; patients without del(17p) are indicated as solid line, and patients carrying del(17p) as hatched line. Tick marks indicate censored data.

Table 1

Patient characteristics.

Patients (N=40)	
Median age (range)	63.2 (35 – 82)
Female	14 (35 %)
Male	26 (65 %)
Rai stage	
I / II	7/4
III	6
IV	23
Del (17p) or <i>TP53</i> mutation, previously treated	16 (40%)
Del (17p) or <i>TP53</i> mutation, previously untreated	4 (10 %)
Del (11q)	13 (32.5 %)
Del (13q)	5 (12.5 %)
FISH negative	2 (5 %)
IGHV gene (unmutated / mutated / unknown)	32 / 1 / 7
Early relapse after chemo-immunotherapy	7
Number of prior treatments (mean, range)	1.9 (1 – 3)
Time to relapse, months (mean, range)	14.4 (2 – 24)
	Median (range)
Prior treatments	2.0 (0 – 8)
Fludarabine, cyclophosphamide, rituximab (FCR)	28
Monoclonal antibodies (rituximab, ofatumumab, alemtuzumab)	18
Bendamustine, rituximab (BR)	9
Other regimen	25
Cycles completed	15 (2 – 21)
Follow-up time (months)	16.8 (2.3 – 20.5)
Hemoglobin (g/dL)	11.7 (6.7 – 15.6)
Platelets ($10^3/\mu\text{L}$)	91.5 (36 – 242)
White blood cell count ($10^3/\mu\text{L}$)	22.4 (2.2 – 297.8)
Absolute lymphocytes ($10^3/\mu\text{L}$)	19.9 (0.4 – 277)
beta-2-microglobulin (mg/L)	4.15 (2.2 – 12.3)

Table 2

Quality of life in CLL patients before (baseline) and after 6 months of treatment with iR. P values correspond to comparison of Z scores. There were significant improvements in global health, functional and symptom scales, and other items.

EORTC – QOL- C30 v.3 Measure	Mean Baseline (n=39)	SD	Mean 6 months (n=36)	SD	Mean difference (95% CI)	p-value
Global health status	70.9	18.8	84.2	12.4	13.3 (6.1, 20.5)	.001
Functioning scale						
Physical	88	17.8	97.6	6.8	9.6 (3.6, 15.6)	.003
Role	90.2	19.0	98.1	7.7	7.9 (1.4, 14.4)	.02
Social	81.6	22.9	97.2	8.4	15.6 (7.9, 23.3)	.001
Emotional	83.8	14.5	97.7	5.8	13.9 (9.0, 18.2)	.001
Cognitive	92.3	12.6	98.6	4.7	6.3 (2.1, 10.5)	.006
Symptom scale						
Nausea/vomiting	20.5	14	1.4	4.7	-19.1 (-23.8, -14.4)	.001
Pain	13.2	25.1	3.7	12.7	-9.5 (-18.4, -0.6)	.04
Fatigue	24.8	23.7	4.9	13.4	-19.9 (-28.5, -11.3)	.001
Single item						
Insomnia	24.8	26.2	7.4	16.1	-17.4 (-29.2, -7.6)	.001
Appetite loss	10.2	17.4	0	0	-10.2 (-15.7, -4.7)	.001
Diarrhea	2.6	9	11.1	19.5	8.5 (1.53, 15.5)	.01
Constipation	6	15	1.8	11.1	-4.2 (-10.1, 1.74)	.18
Dyspnea	19.6	27.3	2.8	9.3	-16.8 (-25.9, -7.7)	.001
Financial impact	12	20.9	3.7	10.6	-8.3 (-15.7, -0.9)	.04

Table 3

Related and unrelated adverse events

Related adverse events	Grade 1	Grade 2	Grade 3	Grade 4
Lung Infection	5	9	2	
Diarrhea	9	1		
Neutropenia			1	1
Fatigue	4	3		
Upper respiratory infection	3	10	1	
Nausea/Acid reflux	10	3		
Arthralgia	8	3		
Transaminase increase			1	
Bleeding events (Bruising/Rash/ Epistaxis)	8	5		
Peripheral neuropathy	1	1	1	
Weight gain		4		
Eye disorders (itching/watery eyes)	1	2		
Mucositis	1	1	1	
Constipation	1			
Alopecia	1			
Atrial Fibrillation	1	1		
Unrelated adverse events	Grade 1	Grade 2	Grade3	Grade 4
UTI (Urinary tract infection)		3		
Insomnia		4		
Headache	3			
Anemia	1	2		
Osteoporosis		1		
Hot flashes		2		
Constipation	1	2		
Nausea/vomiting		2		
Anxiety		2		
Dry mouth	1	1		
Dyspnea		1		
Subdural Hematoma			1	
Sepsis			1	